Disc Medicine Launches Expanded Access for Bitopertin, Eyes Mid-2027 FDA Decision
IRON sits 74% above its 52-week low of $40.
Summary
Disc Medicine launched an Expanded Access Program (EAP) for its investigational drug bitopertin, allowing eligible EPP and XLP patients in the U.S. to gain access. This move demonstrates the company's confidence and commitment to the drug while the Phase 3 APOLLO study continues. The company reiterated expectations for APOLLO data in Q4 2026, with a potential FDA decision by mid-2027.
At the time of this announcement, IRON was trading at $69.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $40.00 to $99.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.